Degron Therapeutics Co-Founder Provides New Strategy for Molecular Glue in Tumor Immunotherapy
Research published in Cell Chemical Biology showed lenalidomide can enhance cancer-treating ability of PD-1 antibody
By Degron, June 28, 2022,
Degron Therapeutics Raises $22M Series A Financing to Accelerate Growth and Expand Molecular-Glue-Based Targeted Protein Degradation Drug Discovery Platform
SAN DIEGO, Calif., and SHANGHAI, China, June 9, 2022 - Degron Therapeutics (“Degron”), a biotechnology company developing a new class of small-molecule medicines that target previously undruggable targets, today announce...
By Degron, June 09,2022
Degron Therapeutics Had an Exclusive Interview with CCTV2 "Economy 30 Minutes" Program
At 8:00 p.m. on March 11, 2022, the prime-time program “Economy 30 Minutes” on CCTV2 broadcast a special report on the Shanghai Pudong Economic Development Zone and highlighted the innovation in life sciences of JLABS in...
By Degron, March 11, 2022
The Theme Activities of "Degron Date" Concluded Successfully
With lush greens and pleasant weather, Shanghai headed into the best March spring. Degron empoyees got together for a special "Degron Date", a series of activities to be held regularly，with different themes com...
By Degron, March 10, 2022
Molecular Glue Degraders，a New Dawn Since PROTACs
Yong Cang, professor of ShanghaiTech University and co-founder of Degron Therapeutics
By Yong Cang, August 18, 2020,